Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Wednesday 27th March 2019 from 11:00 AM to 1:00 PM (GMT).

During this time our website performance may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.


Issue 23, 2013
Previous Article Next Article

UPLC-MS/MS determination and pharmacokinetic study of 26-OH-panaxadiol in rat plasma

Author affiliations

Abstract

Dammar-20S, 25R-epoxy-3β, 12β, 26-triol (26-OH-panaxadiol), the new sapogenin product of the oxidative cyclization of protopanaxadiol from ginseng, exhibits a significant pharmacological effect as an anti-tumor agent. A sensitive and rapid analytical method based on ultra-performance liquid chromatography coupled with tandem mass spectrometry (UPLC-MS/MS) was initially developed for the detection of 26-OH-panaxadiol in rat plasma. Pre-treatment of the sample obtained from the plasma involved a single protein precipitation step using methanol. 26-OH-panaxadiol and an internal standard (IS), tanshinone II A, were separated on a Waters ACQUITY UPLC BEH C18 analytical column (50 mm × 2.1 mm, 1.7 μm) using acetonitrile–0.1% formic acid in water (80 : 20, v/v) as the mobile phase, at a flow rate of 0.3 mL min−1. Chromatography of the 26-OH-panaxadiol and IS was performed within 3 minutes. Detection was performed through positive ion electrospray ionization (ESI+) in multiple reaction monitoring (MRM) mode. The assay was linear over the concentration range of 1–1000 ng mL−1 (r > 0.9960). The limit of detection (LOD) and the lower limit of quantification (LLOQ) were 0.3 ng mL−1 and 1.0 ng mL−1, respectively. The intra- and inter-day deviations (expressed as relative standard deviation, RSD) were ≤4.8% and ≤8.5%, respectively, and the accuracy (expressed as relative error, RE) was in the range of 4.5% to 5.3%. The recoveries of 26-OH-panaxadiol and IS were 91.2% and 98.7%, respectively, and the matrix effects were satisfactory in all of the biological matrices examined. This fully validated method was successfully applied to the pharmacokinetic study of rats after a single initial intragastric administration of 15 mg kg−1 26-OH-panaxadiol. The main pharmaco-kinetic parameters: Tmax (the time to peak), Cmax (the concentration to peak), and t1/2 (the biological half life) were 3.08 ± 1.24 h, 2833.86 ± 1246.08 μg L−1, 5.14 ± 1.01 h, respectively.

Graphical abstract: UPLC-MS/MS determination and pharmacokinetic study of 26-OH-panaxadiol in rat plasma

Back to tab navigation

Publication details

The article was received on 02 Aug 2013, accepted on 20 Sep 2013 and first published on 20 Sep 2013


Article type: Paper
DOI: 10.1039/C3AY41320A
Citation: Anal. Methods, 2013,5, 6656-6662

  •   Request permissions

    UPLC-MS/MS determination and pharmacokinetic study of 26-OH-panaxadiol in rat plasma

    M. Lin, H. Gao, J. Liu, L. Han, Q. Zhang and P. Li, Anal. Methods, 2013, 5, 6656
    DOI: 10.1039/C3AY41320A

Search articles by author

Spotlight

Advertisements